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BACKGROUND
Thc period from conception til l adulthood is characterised by specific
developmental proccsses that are of influence on the way how drugs are
handled. Both prenatal and postnatal drug exposure may result in a broad
range of expccted and unexpected effects, and there are many pathways
through rvhich exposure may occur in this period. In view of these specif ic
pharmacotherapeutic aspects during devclopment, the aim of this thesis was to
dcscribe drug exposure from conception til l adulthood and to identify problem
arcas related to drug exposure in this period.
PART I . METHODOLOGICAL ASPECTS
Previous studies have demonstrated that dispensing data from Dutch
pharmacies offer an accurate survey of thc use of prescription drugs, and in
many chapters of this thesis pharmacy dispensing data is therefore used as an
approximation for drug use.
An important problem in thc assessment of drug use by future fathers
and futurc mothers using pharmacy data is,  however,  that nei ther pregnancy,
nor chi ld-parent relat ions are rout inely documented in pharmacies. In
Chapter 1, therefore, we thought out a method for retrospectively identifying
parents in pharmacy data, just pr ior to and during pregnancy, and establ ished
the validity of this method. We applied it to the records of all 4 pharmacies in
1 town, and determined the yield by comparison of the number of identified
parents with the total number of parents in the town (based on figures from
Stat ist ics Netherlands),  and determined the correctness based on several
validation criterions evaluatcd by pharmacy employees and gcneral
pract i t ioners. The results of this val idat ion showed that retrospect ive
identification of parents in pharmacy data is feasible in a valid way, but that
the main l imitat ion is that not al l  parents can be found, possibly result ing in
select ion bias.
Another methodological problem related to the use of pharmacy
dispensing data is that the population that is covered by pharmacies is often
dif f icul t  to determine. In Chapter 2 we evaluated two methods using drug
ut i l isat ion information to est imate the populat ion size: a drug-use-based
extrapolation of a known part of the population, and a capture-recapture
est imation without any pr ior knowledge of the populat ion. Using pharmacy
dispensing data of three towns with known populat ions in the Netherlands, we


































proport ion of drug-using inhabitants.  In addit ion, we appl ied two-source and
threc-source capturc recapture models with al l  combinat ions of the fol lowing
drug groups as cl i f ferent s()urces: ant i -asthmatics, anir lgesics, ant ibiot ics and
ant i-histamincs. Our f indings suggestecl  that i f  a part  of  the populat ion is
known, and i f  there is reason to assume that drug ut i l isat ion patterns do not
vary within the region, i t  is best to usc drug-use-bascd extrapolat ion. In al l
other si tuat ions capture-recapture may be considered, rvi th as rn: i in l imitat ion
that we found al l  modcls to underest imate the populat ion considerably.
PART II . GENERAL DRUG UTILTSATION STUDIES F'ROM
CONCEPTION TILL AD ULTHOOD
In the sccond part  of  the thesis several  aspects of drug use of future fathers,
drug use of pregnant women, drug usc during bir th,  drug use of lactat ing
women and drug use of chi ldren werc invest igated.
Despite the increasing attent ion for thc role of paternal exposures around the
period of concept ion, thcre is no factual inforrnat ion about drug ut i l izat ion o1'
fathers. In Chapter 3, therefore, we describecl  thc drugs dispensed to fathers
around concept ion, using pharmacy dispcnsing data of community pharmacics
in Denmark and the Netherlands. We found that one third of al l  fathers had
t i iken up prcscr ipt ions for at  lcast or-rc drug in the half  year before concept ion,
both in Denmark and in the Nctherlands. In the major i ty of fathers only one
typc of drug was dispensed, but in both countr ies at least 57a of al l  fathers had
redeemed three or more types of drugs. The main drugs purchascd by fathers
in Denmark and the Netherlands were ant ibiot ics (14.3% and ó.3olo of al l
fathers, respect ively),  anaigesics (6.ro/o and 7.6%), ant ihistamines (2.0% and
2.0%) and ant i-ulcer drugs (1.6c/o and 2.5o/o).  We concludcd that a large
proport ion of fathcrs used drugs in the prcconce.pt ion pcr iod, and that this
emphasises the importance of safety information on therapeut ic drugs rvi th
rcspect to potent ial  paternal tcratogenici ty.
In Chapter 4 drug usc during pregnancy was examine d. ' l ' l ie
interpretat ion of the avai lable studies of drug use in pregnancy is oftcn
hampered bccause i t  is not c lear to what extcnt women have changed their
drug choice. Basecl on pharmacy data we dcscr ibed drug use in prcgnancy, and
compared drug use of pregnant women and comparable non-pregnant wome n,
both with reference to the Austral ian r isk classi f icat ion system. Overal l ,  3-5%
of al l  prescr ipt ions for non-pregnant womcn were classi f ied as safe for usc in
pregnancy (Australian classification A), I4o/c' rvere classified as drugs with an
unknown r isk (B1 ,F2),  4970 were potent ial ly harrnful  drugs (B3,C,D,X),  and
199
for 37o the drug was not includccl in the classification. For pregnant women
these f igures wcrc 86, 3, 10 and2o/c respect ively.  In non-pregnant women drug
groups with thc highest percentagcs of prescr ipt ions for unsafe drugs were
psycholept ics (99% of the prescr ipt ions not classi f ied as safe),
psychoanalept ics (1007o),  ant i - inf lammatory and ant irheumetic products
( l00Vc),  systcr.nic ant ihistamines (917o),  drugs for acid related disorders
(817o),  ant ie pi lept ics (700o/o),  beta blocking agents ( I004/o),  systemic
ant imycot ics (  1007o),  ant iprotozoals (977o),  c l iuret ics (100%) and
immunosuppressive agents (100%). In pregnant women this pattern was
comparable. except for systemic antihistamines (22o/c,) and drugs for acid
related disorders (3%), We concluded that many drugs used by non-prcgnant
women should be avoided in prcgnancy, and that prcgnant women indeed do
so. Our f indings suggested, however,  that for a number of drug groups the
avai lable safe al tcrnat ives are l imitcd.
Drug use during chi ldbir th was examincd in Chapter 5. Using a
prospect ive reeistrat ion by community midwivcs of medicat ion use during
bir ths outside the hospital .  we found that medicat ion was used in 58.4%' of the
del iver ies outsic le the hospital ,  with an averagc of 1.4 drug per del ivery. The
drugs used most ly were oxytocine (35.6Vo of al l  del iver ies) and local
anesthet ics (32.9%,).  When mcdicat ion was used, i t  was administered before
cutting the umbilical cord in 16.77o of the cases. Prophylactic or routine
administrat ion, local anesthesia, postpartum hentorrhages and retained
placenta were thc most frequcnt indicat ions for using medicat ion. We
concludcd that the use of mcdicat ion during chi ldbir th outside the hospital  in
the Netherlands rvas low and chi ldren were minimal ly exposed to medicat ion.
In Chapter 6 we surveyed drug use by breastfeeding women, and
compared this with non-brcastfeeding women. In addit ion, we examined
whether drug use was of influcncc on the decision to give breastfeeding, and
the other way around. During a 6-week period a qucst ionnaire was handed out
to al l  women with a chi ld not oldcr than 6 months, who visi ted a Wcl l-Baby
Clinic.  Morc than half  (65.9o/r.)  of  al l  breastfeeding women had used drugs,
however they r"rscd drugs less frequent ly than non-breastfeeding women
(19.6%). Also thc pattern of c lrug use di f fcrcd: oral  contracept ivcs, i ron
preparations, clrugs for peptic ulcer, and several psychotropic drugs wcrc more
frequent ly uscd by non-breastfceding women, whi le vi tamins werc more
frequent ly uscd by breastfeedins women. Our f indings further incl icated that
drugs plary an important role in breastfeeding: wonren frequent ly hesi tated to
use drugs during breastfeedin-q, stopped ei ther breastfeeding or drug use to
avoid combining the two, took a measure to minimize exposure to the chi ld,
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of drug use. We concludcd that drugs are frequent lv thorrqh relrrctalr t iv t rsr-r l
dur ing  bre l l s t fced ing .  and tha t  d rugs  p lay  an  impor ta r i t  ro le  i t r  1 l i r , ' q icc iq ip r r  t r
start  and stop breastfeeding. Tl i is emphasises that infornral ion l rr111, , . . r  r l . l i
wi th drugs is indispe nsablc in efforts to prontote br i :astfei :c l ing.
ln the last chaptcr of  this part ,  Chapter ?. r i r r-rr t  r tsr.  rr Í , r 'h ikh:rr  r , . ; rs
assessed using pharmacy clata. Wc founcl that druc use wris l l r l  h ighrrst  i ln l(r1.r l l
infants,  dccreaseci t i l l  adolescencc ancl incrclrse r l Í l 'orr l  rher i :  (  ivr :r-r i l l .
approximately 6L)% of al l  chi ldren usecl at  least onc dnrg i rr  1t) !) ,8 Al vorrrrgr-r
age. boys used more drugs than gir ls ancl  at  oldcr age gir ls rrse.r l  nrr l rr :  r . inrqq
than boys. Systernic antibiotics were usecl 'ty 2L(/c of the children urrrJ rv6lre fi,
far the most widely used drugs. Other frequent ly rrsccl  r l r r , rgs wctc r i rraigt)sir-- .c
(10%), cort icosteroids for dcrmatolosic usc (9o,( ) .  unt l r ist ; rnine,s (8i) l '1 ar i i l
anti-astlrmzftics(7a,('). ApproximaÍely l{)cio of the chilclren hiicl rrscrl i ir lr:rsf onr
clrug at the age of 1 rnonth and at thc age of 2 r ,eirrs Íhis prolroi ' t ion r ,r , 'a-s,gl í . / í , .
We concluded that the major i ty of chi ldren was exposr:r l  l r . r  orrr :  { , r  Í i l { )rc cl l r r .sc
i ind t l rat  this cxposLrrc startcd at verv younI agc"
PART III . DRUG USE AFTER BIRTH IN MORE DETAII,
Several  aspects of drug use after bir th were cxarninct i  i r r  rnore r icr;r i l  in the:
t h i r d  p a r t  o f  t h i s  d i s s c r t a t i o n .
In Chapter 8 we invest igated the use of psychotropic nrccl icat iorr  i r r
chi ldrcn in the Netherlands using pharmacy disponsing data, and compurecl
this with earl ier reporteci  f isures from the United States oÍ Anrer ic;r  í t i . í i .A).
Wc found that st imulants were used to the greatcst extent by ()-19-vcar-olr ls
(prevalence 7 .411000 in 1999),  fol lowed by hypnot ics/anxiolyt ics ( ír .9/  t0(X)) arrct
ant idepressants (4.21l1000).  Prevalence rates of st imulnnts jncrcaser-1 fronr
1.5/1000 in 199-5 to 7.411000 in 1999. Incidcnce rates, proporf ion of s{r ls.  i }n( l
durat ion of st imulant treatment increased too. Changes in l t rcvalcrncc rales oi
other psl ,chotropics lvere much smal lcr than thosc of st i rnul lnts.  Fin3l lv.  t l r t -
vast major i ty of chi ldren treated with psychotropic a.gents rrsecl  ol ly 9nc
psychotropic.  I t  was concluded that prevalence of st intulant usr:  i r r  the
Nethcr lands is much lower than earl ier reporred from the I ,J.S.A. í l .g i l0(Xl
chi ldren in 1995) and cl i f ferences also exrsted with regard to the use of qthr:r
psychotropics and combinat ions of psychotropics. However,  the inc-retrrsc i1
Dutch st imulant use agrees with the earl ier reporter l  2.-5-Í 'q lc l  i l icrr ,rasr--  i6 thr: .
U.S.A.,  and shows that the increased use of st imulants i_s nrrt  l inr i t t .d l r i  lhe
Uni tcd  Sta tes  o f  Amer ica .
2() Í
Chapter 9 focussed on ant i-asthma mcdicat iort ,  and describecl  the
choicc of drugs as wel l  as the dosagc forms of ant i -asthmatic ' l rugs in chi ldren
with rcgarcl  to di f í 'erent agc groups, bascd on pharmacy dispcnsing data.
Inh:r lcd bc1:r l -aqonists und inhaled cort icosteroicls rverc the most rvidely used
ant i-usthmutic r i rugs in ul l  acc groups (rcspect ively 59 and -58 users per 100
Irnt i -asthrnut ic usirrg 0-16 year-olds).  Cronrones werc r i i relv used. Up to four
ycars r : f  l rge thc uso of t reatment with aerosol inhalers incrcased
simul l i rneously with a dccreasc of oral  dosage Í 'orrns. ' [ ' i re use of dry powder
i l thalcrs sturted i r t  the age of approxinrately 4years old and increased to about
E.5' ,) i ,  of thc users at the age of 11, rv i t l t  thc strongest increasc around thc agc
of 6 ancl 7.  Wc concluded that the choice of drugs and dosage forms
corrcsponds rvi th rvhut might bc cxpecte d based on guidel incs for thc
trcatnrcnt of  i isthnra in chi ldrcn, exccpt 1 'or thc high use oÍ '  deptropine in the
youngcst agc groLlp. Ant i-asthmatic drugs for prcvent ivc treatment are uscd so
Í icr lucnt ly '  u ' r thout bcta2-agonists that qucst ions arbout possible ovcrtreatment
n tc r l  to  hc  n r isec l .
The ainrs of Chapter l0 rvere, f i rst ly.  to determine the amount of
rrrr i i ' - ' , . 'nscr l  prescl ipt i r lns for chi lc lrcn in thc community,  ancl  secondly,  for al l
r i i ' r rus * ' i th u product l icensc, to invest igi t te paediatr ic label l ing in detai l  tcr
dete rr l ine the cxfcnt oÍ 'ot f- labe I  drug use. tJsing pharrnacy cl ispensing data wc
found that many l iccnsed drugs that rvcre usccl  by chi ldren were poorly
lalrcllcd for use in children: it 20.6c/t, of thc casos, use in children was not evcn
nrent ioned in the product l icense, and in 19.67o chi ldren were mentioned
withotrt  any indicat ion of agc. Unl iccnsed (16.60/o f  al l  prescr ipt ions) aird off-
label (22.7%) drug usc was frequent among chi ldren in the conrrnunity.  We
concluded that many l icensed drugs that chi ldrcn use outside the hospitai  arc
poorly labcl led with respect o use in chi ldren, rcsult ing in high pcrcentages of
off- label drug usc.
Risk factors of unl iccnsed and off- labcl  drug use by chi ldren outside
the  hosp i ta l rverc  xamined in  Chapter  l l .  We used pharmacy d ispens ing  da ta ,
and performed a logist ic rcgression was donc that models the odds of
recciving an unl icenscd or off- label prcscr ipt ion as a l 'unct ion of several
possible r isk factors. Wc found that unl iccnsed drug use in Dutch chi ldren is
the highest among 0-1-year-olds, and of l - label drug use is the highest among
12-16-year-olds. Drug groups with highest percentagcs of unl icenscd and oÍf-
labcl  drug usc wcre ophthalmologics/otologicals (80.77c of al l  prescr ipt ions in
this group),  blood and blood forming organs (mainly vi tai l in K for brcastfed
neri l rorns) (75.7o/r) ,  cardiovascular drugs (74.7o/c.)  and dcrmatologicals
(73.31L).  Prescr ipt ions by spccial ists (outpat ient) ,  prcscr ipt ions for new drugs,


















prescr ipt ions for in l 'ants wcre r isk fuctors for using a sy'stemic drug unl icenscd
or off- label.
Appropriate closage forms arc csse nt ial  in pae dintr ic
pharmacotherapy. In Chapter 12 thercfore, we sun'cycd the use o1'  di f fcrent
dosagc fornls by chi ldren in the comrnunitv,  and examined thc reported lack of
l iquid dosage forms and closage forms of thc appropriate str(-ngth. hoth in
re la t ion  to  the  l i cens ing  s ta tus  (au thor isec l ,  o f f - labe l  o r  un l i ccnsec l )  o l ' the
drugs .  Wc founc l  tha t  in  a l l  age  groups .  approx in ra te l ; r  ha l f  o Í ' l t l l  p rescr ip t ions
rvcrc for systenric drugs. The only nrajor agc-relatcd changcs r i 'cre n' i t l i in
systcmic clrugs rvi th y()unger chi ldrcn morc l ikcly to be prescr ibcd ont l
solut ions. For : , iuthor iscd rugs the proport ion of tablet/c irpsulcs cxcecdccl
oral  solut ions at the age of 7 ycars, whcrei ts for of f- label drugs this occr-rrrcd u1
3 ycars of agc. Prescr ipt ions with a dosage form that was classi f icd a:r  tor-r
strong rverc almost cxclusively for.rnd jn thc {r()up of Ltnl iccnsed/ol f- label
prescr ipt ions. espccial l ,v for chi ldren undcr thc ugc o1' ; l  ycars. Wc concluclccl
that thc lack of l iccnsing results in a lack of l iquid dosage forms and dosage
forms with the uppropriatc strcnct l - l .  In acldi t ion to thc unknown safcty anci
cl f icacy aspects of unl iccnsecl and oÍf- labcl  drugs. thcsc f indinus cnrphasisc the
irnport i ince oÍ '  labcl l ing for chi lc lrcn.
Final ly.  Chapter 13 lookcd at advcrsc drug react ions (ADRs). The
interpretat ion of the avai lablc studics on ADRs ir-r  chi ldren outsidc the
hosp i ta l  i s  hampered becausc  nonc  o f  thcse  s tud ies  used a  cont ro l  g roup.  The
aim of this study was to descr ibe ADRs in chi lc lrcn outside thc hospital ,
control lcd for drug use in the pecl iatr ic backgroLrncl  populat ion. Using a casc-
control  dcsign, we compared drugs on which a suspectcd ADR w;rs rcportcd
to the Ncthcr lands Pharmacovigi lance Centre LAREII,  and drugs used in the
general  pacdiatr ic populat ion from the lntcrAct ion pharmacy database. ' I 'he
nrain f indings wcrc that ADRs werc disproport ionately more often rc 'portc 'd
on sys temic  d rugs  (OR 3 .0 ,  [C I9 ,5% 1 .9-4 .8 ] ) ,  nerv  d rugs  (2 .1 ;  [1 .6 -2 .7 ] ) ,  an t i -
in fec t i ve  d rugs  (1 .7 ;  p .1 -2 .1 ) )  anc l  nervous  sys tcm drugs  (2 .1 ;  [1 .3"3 . ,5 ] ) ,
whereas  un l i ccnsed rugs  (0 .  t ;  [0 .0 -0 .a ] ) ,  f rcquent ly  used drugs  (0 .3 ;  [0 .2 -0 .5 ] ) ,
and dermatologicals (0.1; [0.0-0.4])  wcrc lcss l ikely to be assctciatcd with a
rcportcd ADR. Ovcral l .  thc proport ion of 'ol ' f - labcl  prcscr ipt ions did not di f fe r
bctween drugs suspected of an ADR ancl drugs uscd by chi lc lre n in a general
populat ion. We concluded that the pattcrn of drugs associatecl  rv i th a rcporte d
ADR could not be solely explained on basis of drug ut i l isat ion patterns in the

























Stuclies that chat acterise exposure are needed to identify and understand all
potential probierns with drug use, and to set targets for intervention strategies.
"Ifris tiicsis Íias shown that throughout the entire period from conception til l
aclultliood r"irug exposure is considerable. Shortcomings in both knowledge
arid ll ic tiisseininatictt of knowledge make that pharmacotherapy in this period
is cflaraeterised by liniitations, either by a limited number drugs with sufficient
slfety irrfolr.ralirrn to choose from, or by use of drugs with limited safety
infur-nratioir. T'o inerease our knowledge, more efforts should be made to
rt:g,istel' and evaluate actual drug exposures and their outcomes. The results of
this ttresis will hopefully increase the awareness of the problems associated
witli clrug exposure between conception and adulthood, so that adequate
aelic,ns will be taken.
ZU.l
